Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,987,779
  • Shares Outstanding, K 70,037
  • Annual Sales, $ 351,410 K
  • Annual Income, $ -454,030 K
  • 60-Month Beta 1.24
  • Price/Sales 8.36
  • Price/Cash Flow N/A
  • Price/Book 4.33
Trade RARE with:

Options Overview Details

View History
  • Implied Volatility 60.15% ( -7.07%)
  • Historical Volatility 44.32%
  • IV Percentile 51%
  • IV Rank 37.50%
  • IV High 92.52% on 07/11/22
  • IV Low 40.73% on 01/14/22
  • Put/Call Vol Ratio 3.33
  • Today's Volume 13
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 8,223
  • Open Int (30-Day) 7,779

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -2.13
  • Number of Estimates 10
  • High Estimate -1.09
  • Low Estimate -3.04
  • Prior Year -1.08
  • Growth Rate Est. (year over year) -97.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.55 +2.50%
on 09/29/22
49.98 -18.89%
on 09/12/22
-7.21 (-15.10%)
since 09/02/22
3-Month
39.55 +2.50%
on 09/29/22
68.68 -40.97%
on 07/13/22
-23.26 (-36.46%)
since 07/05/22
52-Week
39.55 +2.50%
on 09/29/22
89.56 -54.73%
on 11/03/21
-46.58 (-53.47%)
since 10/05/21

Most Recent Stories

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 40.54 (-4.97%)
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

RARE : 40.54 (-4.97%)
ABEO : 3.21 (-5.87%)
SRRK : 8.01 (+0.50%)
BNTX : 137.19 (-0.28%)
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RARE : 40.54 (-4.97%)
ANIP : 32.84 (-0.36%)
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories1 of $64.0 million Reaffirm 2022 Crysvita revenue in...

RARE : 40.54 (-4.97%)
Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 40.54 (-4.97%)
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE : 40.54 (-4.97%)
ALNY : 201.02 (-0.11%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 40.54 (-4.97%)
Why Ultragenyx Pharmaceutical Stock Is Cratering Today

Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.

RARE : 40.54 (-4.97%)
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

BEAM : 50.95 (-1.26%)
ANIK : 24.63 (+0.29%)
RARE : 40.54 (-4.97%)
FATE : 23.56 (-1.13%)
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to...

RARE : 40.54 (-4.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 43.64
2nd Resistance Point 43.01
1st Resistance Point 41.78
Last Price 40.54
1st Support Level 39.92
2nd Support Level 39.29
3rd Support Level 38.06

See More

52-Week High 89.56
Fibonacci 61.8% 70.46
Fibonacci 50% 64.56
Fibonacci 38.2% 58.65
Last Price 40.54
52-Week Low 39.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar